Evidence map›Paper›PMID 32557280›Full record

ArticleMolecular diversity2021

Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.

Pedro Igor Camara de Oliveira, Paulo Henrique de Santana Miranda, Estela Mariana Guimaraes Lourenço, Priscilla Suene de Santana Nogueira Silverio, Euzebio Guimaraes Barbosa

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pedro Igor Camara de OliveiraPrograma de Pós-Graduação em Bioinformática, Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, UFRN, Rua Gen. Gustavo Cordeiro de Faria, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.ORCID http://orcid.org/0000-0001-7801-171X
Paulo Henrique de Santana MirandaPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, UFRN, Rua Gen. Gustavo Cordeiro de Faria, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.ORCID http://orcid.org/0000-0002-7893-8408
Estela Mariana Guimaraes LourençoPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, UFRN, Rua Gen. Gustavo Cordeiro de Faria, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.ORCID http://orcid.org/0000-0003-2708-4526
Priscilla Suene de Santana Nogueira SilverioPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, UFRN, Rua Gen. Gustavo Cordeiro de Faria, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.ORCID http://orcid.org/0000-0003-1687-6907
Euzebio Guimaraes BarbosaPrograma de Pós-Graduação em Bioinformática, Faculdade de Farmácia, Universidade Federal do Rio Grande do Norte, UFRN, Rua Gen. Gustavo Cordeiro de Faria, S/N - Petrópolis, Natal, RN, 59012-570, Brazil. euzebiogb@imd.ufrn.br.ORCID http://orcid.org/0000-0002-7685-9618
Universidade Federal do Rio Grande do Norte · BR

Funding

CAPES 001
6 · The paper itself

Abstract

Chagas disease kills over 10,000 people per year, and approximately 8 million people are infected by Trypanosoma cruzi. The reference drug for treatment of the disease, benznidazole, is the same since the 70s. In recent years, many CYP51 inhibitors were tested against this parasite's target. One of them, posaconazole, was even tested in clinical trials that unfortunately were not successful. Nevertheless, there are still many evidences that CYP51 is a great potential target to treat T. cruzi infection. The research for new effective molecules that can cure the chronic phase of the disease is essential. 2D and 3D-quantitative structure activity relationship (QSAR) studies were conducted in this work to create three QSAR models using the chemical structures of 197 published compounds that already went through either in vivo or in vitro tests. After the analysis of the models, new analogues not yet synthesized were suggested here and had their biological activity and synthetic availability assessed.

Indexed as

14-alpha Demethylase InhibitorsQuantitative Structure-Activity RelationshipTrypanosoma cruziChagas DiseaseCytochrome P-450 Enzyme SystemHumansModels, MolecularSterol 14-DemethylaseTrypanocidal Agents14-alpha Demethylase InhibitorsCYP51 protein, Trypanosoma cruziCytochrome P-450 Enzyme SystemSterol 14-DemethylaseTrypanocidal AgentsChagas diseaseCYP51QSARStructure-based drug designTrypanosoma cruzi

Identifiers

PMID32557280
OpenAlexW3036955938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.